340B Drug Pricing Program
The AHA July 13 criticized proposed deep cuts to how much the Centers for Medicare & Medicaid Services reimburses hospitals for drugs acquired under the 340B Drug Pricing Program and proposes changes to site-neutral payment policies under Section 603 of the 2015 Bipartisan Budget Act.
On July 13, the CMS released two calendar year 2018 proposed rules: the outpatient prospective payment system/ambulatory surgical center proposed rule and the Medicare physician fee schedule proposed rule.
The Centers for Medicare & Medicaid Services today proposed to update hospital outpatient prospective payment system rates by 1.75% in calendar year 2018 compared to CY 2017. The rule also would drastically cut Medicare payment for drugs that are acquired under the 340B Drug Pricing…
Today, CMS issued several poorly designed policies that will do real damage to patients access to care.
Reps. Peter Welch (D-VT) and Gregg Harper (R-MS) yesterday introduced the Closing Loopholes for Orphan Drugs Act (H.R. 2889, legislation that would limit the “orphan drug” exclusion for 340B Drug Pricing Program rural and cancer hospitals.
The skyrocketing price of prescription drugs threatens both patient access to care and the ability of providers to deliver the highest quality of care to patients and communities.
The Health Resources and Services Administration today delayed to Oct. 1 the effective date of its final rule on 340B drug ceiling prices and civil monetary penalties for manufacturers. The final rule was subject to multiple delays since January.
The Health Resources and Services Administration today delayed to May 22 the effective date of its final rule on 340B drug ceiling prices and civil monetary penalties for manufacturers, and invited comments on whether a delay to Oct. 1 would be more appropriate.
“Congress should preserve the 340B Drug Pricing Program and protect patients and communities,” writes AHA Executive Vice President Tom Nickels in an AHA Stat blog post. He notes, “Every day, we see stories about the exorbitant costs of prescription drugs and the serious challenges they pose for…